<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953561</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0444</org_study_id>
    <secondary_id>NCI-2016-01924</secondary_id>
    <secondary_id>2016-0444</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02953561</nct_id>
  </id_info>
  <brief_title>Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label Phase Ib/II Study of Avelumab in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trial studies the best dose and side effects of avelumab when given together&#xD;
      with azacitidine and to see how well they work in treating patients with acute myeloid&#xD;
      leukemia that is not responding to treatment or has come back. Monoclonal antibodies, such as&#xD;
      avelumab, may interfere with the ability of cancer cells to grow and spread. Azacitidine may&#xD;
      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.&#xD;
      Giving avelumab and azacitidine may work better in treating patients with acute myeloid&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of avelumab&#xD;
      in combination with azacitidine (5-azacytidine) in patients with refractory/relapsed acute&#xD;
      myeloid leukemia (AML). (Phase IB)&#xD;
&#xD;
      II. To determine the overall response rate (ORR) defined as complete remission (CR)/complete&#xD;
      remission with incomplete platelet recovery (CRp)/complete remission with incomplete count&#xD;
      recovery (CRi)/partial remission (PR)/hematologic improvement (HI)/morphologic leukemia free&#xD;
      state (MLFS) of avelumab in combination with 5-azacytidine in patients with&#xD;
      refractory/relapsed AML. (Phase II&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the number of patients achieve &gt; 50% reduction in blasts on therapy with this&#xD;
      combination.&#xD;
&#xD;
      II. To determine the duration of response, disease-free survival (DFS), and overall survival&#xD;
      (OS) of patients with refractory/relapsed AML treated with this combination&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To study immunological and molecular features at baseline and at predefined time-points&#xD;
      on-therapy with avelumab and azacytidine in the peripheral blood and bone marrow to include&#xD;
      quantify immune ligand expression by the AML blasts and AML stromal components&#xD;
      (myeloid-derived suppressor cells [MDSCs] and mesenchymal stem cells [MSCs]) including&#xD;
      4-1BBL, ICOSL, PD-L1, PD-L2, OX-40L, CD137L.&#xD;
&#xD;
      II. To study immunological and molecular features at baseline and at predefined time-points&#xD;
      on-therapy with avelumab and azacytidine in the peripheral blood and bone marrow to determine&#xD;
      the quantitative expression of positive and negative co-stimulatory molecules on individual&#xD;
      T-lymphocyte subsets including 4-1BB, CTLA-4, ICOS, PD-1, OX40, LAG-3 and TIM-3.&#xD;
&#xD;
      III. To study immunological and molecular features at baseline and at predefined time-points&#xD;
      on-therapy with avelumab and azacytidine in the peripheral blood and bone marrow to identify&#xD;
      the immunophenotype of tumor-infiltrating T-lymphocytes (TILs) pre- and post-therapy with the&#xD;
      combination: CD8+, CD4+ effector, or CD4+ regulatory.&#xD;
&#xD;
      IV. To develop a micro-array based gene expression profile (GEP) predictor of response to&#xD;
      anti-PDL1 and epigenetic therapy in AML.&#xD;
&#xD;
      V. To determine the correlation of responses to the combination with baseline cytogenetic and&#xD;
      molecular abnormalities&#xD;
&#xD;
      OUTLINE: This is a phase Ib, dose-escalation study of avelumab followed by a phase II study&#xD;
&#xD;
      Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 10-40 minutes on&#xD;
      days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1&#xD;
      and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3-6 months for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PDOL request&#xD;
  </why_stopped>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Complete Response (CR) + Partial Remission (PR) + Complete Remission with incomplete recovery (CRi) + Clinical Benefit. CR = normalization of peripheral blood (PB) and bone marrow (BM) with &lt;/= 5% BM blasts, PB granulocyte count &gt;/= (1.0 x 10^9/L, and a platelet count &gt;/= 100 x 10^9/L). PR = same as CR except presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. CRi meets all criteria for CR except for platelet recovery to &gt;100 x 10^9/L and/or granulocyte count &gt; (1.0 x 10^9/L). MLFS is BM with &lt;/= 5% BM blasts with no PB recovery. Hematologic Improvement is platelets increase by &gt;/= 30 x 10^9/L untransfused (if &lt;20 at pretherapy); or granulocytes increase by 100% and to &gt;0.5 x 10^9/L (if lower than that pre-therapy); or hemoglobin increase by 2 g/dl; or transfusion independent; or splenomegaly reduction by &gt; 50%; or monocytosis reduction by &gt; 50% if pretreatment &gt; 5 x 109/L, or BM or PB Blasts decrease by &gt;/= 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Distribution of OS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Distribution of PFS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (azacitidine, avelumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, avelumab)</arm_group_label>
    <other_name>Bavencio</other_name>
    <other_name>MSB-0010718C</other_name>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given SC or IV</description>
    <arm_group_label>Treatment (azacitidine, avelumab)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, avelumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with AML who are refractory (up to salvage 2) or relapsed (up to 2nd&#xD;
             relapse); for patients with prior myelodysplastic syndrome (MDS) or chronic&#xD;
             myelomonocytic leukemia (CMML) or myeloproliferative neoplasm (MPN) who transformed to&#xD;
             AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML&#xD;
&#xD;
          -  Prior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g.&#xD;
             FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 times upper limit of normal (x ULN) (=&lt; 3 x ULN if considered&#xD;
             to be due to leukemic involvement or Gilbert's syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase or alanine aminotransferase =&lt; 2.5 x ULN (=&lt; 5.0 x ULN if&#xD;
             considered to be due to leukemic involvement)&#xD;
&#xD;
          -  Estimated creatinine clearance &gt;= 30 mL/min according to the Cockcroft-Gault formula&#xD;
             (or local institutional standard method)&#xD;
&#xD;
          -  Patients must provide written informed consent&#xD;
&#xD;
          -  In the absence of rapidly progressing disease, the interval from prior treatment to&#xD;
             time of initiation of 5-azacytidine and avelumab will be at least 14 days OR at least&#xD;
             5 half-lives for cytotoxic/noncytotoxic agents, whichever is longer; the toxicity from&#xD;
             prior therapy should have resolved to grade =&lt; 1, however alopecia and sensory&#xD;
             neuropathy grade =&lt; 2 is acceptable; the half-life for the therapy in question will be&#xD;
             based on published pharmacokinetic literature (abstracts, manuscripts, investigator&#xD;
             brochures, or drug-administration manuals) and will be documented in the protocol&#xD;
             eligibility document; use of hydroxyurea for patients with rapidly proliferative&#xD;
             disease is allowed before the start of study therapy and will not require a washout;&#xD;
             concurrent therapy for central nervous system (CNS) prophylaxis or continuation of&#xD;
             therapy for controlled CNS disease is permitted; patients with CNS disease or leukemic&#xD;
             brain metastasis must have been treated locally and be clinically stable for at least&#xD;
             2 weeks prior to enrollment and have no ongoing neurological symptoms that are related&#xD;
             to the CNS disease (sequelae that are a consequence of the treatment of the CNS&#xD;
             disease are acceptable)&#xD;
&#xD;
          -  Females must be surgically or biologically sterile or postmenopausal (amenorrheic for&#xD;
             at least 12 months) or if of childbearing potential, must have a negative serum or&#xD;
             urine pregnancy test within 72 hours before the start of the treatment&#xD;
&#xD;
          -  Women of childbearing potential must agree to use an adequate method of contraception&#xD;
             during the study and until 3 months after the last treatment; males must be surgically&#xD;
             or biologically sterile or agree to use an adequate method of contraception during the&#xD;
             study until 3 months after the last treatment; adequate methods of contraception&#xD;
             include:&#xD;
&#xD;
               -  Total abstinence when this is in line with the preferred and usual lifestyle of&#xD;
                  the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment;&#xD;
                  in case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
                  been confirmed by follow up hormone level assessment&#xD;
&#xD;
               -  Male sterilization (at least 6 months prior to screening); for female patients on&#xD;
                  the study, the vasectomized male partner should be the sole partner for that&#xD;
                  patient&#xD;
&#xD;
               -  Combination of any of the two following (a+b or a+c or b+c)&#xD;
&#xD;
                    -  a. Use of oral, injected or implanted hormonal methods of contraception or&#xD;
                       other forms of hormonal contraception that have comparable efficacy (failure&#xD;
                       rate &lt; 1%), for example hormone vaginal ring or transdermal hormone&#xD;
                       contraception&#xD;
&#xD;
                    -  b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
                    -  c. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal&#xD;
                       suppository In case of use of oral contraception, women should have been&#xD;
                       stable on the same pill before taking study treatment&#xD;
&#xD;
               -  Note: oral contraceptives are allowed but should be used in conjunction with a&#xD;
                  barrier method of contraception due to unknown effect of drug-drug interaction&#xD;
&#xD;
          -  Women are considered post-menopausal and not of child bearing potential if they have&#xD;
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile&#xD;
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago;&#xD;
             in the case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
             been confirmed by follow up hormone level assessment is she considered not of child&#xD;
             bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known allergy or hypersensitivity to avelumab, 5-azacytidine, or any&#xD;
             of their components; known severe hypersensitivity reactions to monoclonal antibodies&#xD;
             (grade &gt;= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse&#xD;
             Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma&#xD;
             (that is, 3 or more features of partially controlled asthma)&#xD;
&#xD;
          -  Patients with a known history of severe interstitial lung disease or severe&#xD;
             pneumonitis or active pneumonitis/pneumonia or pulmonary pathology that is not well&#xD;
             controlled in the opinion of the treating physician and/or principal investigator (PI)&#xD;
&#xD;
          -  Patients who have previously been treated with avelumab (or another PD1/PDL1&#xD;
             inhibitor) in combination with 5-azacytidine will be excluded&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy of grade &gt; 1 NCI-CTCAE v 4.03; however,&#xD;
             alopecia and sensory neuropathy grade =&lt; 2 is acceptable&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent: a) subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid&#xD;
             disease not requiring immunosuppressive treatment are eligible; b) subjects requiring&#xD;
             hormone replacement with corticosteroids are eligible if the steroids are administered&#xD;
             only for the purpose of hormonal replacement and at doses =&lt; 10 mg or 10 mg equivalent&#xD;
             prednisone per day; c) administration of steroids through a route known to result in a&#xD;
             minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are&#xD;
             acceptable&#xD;
&#xD;
          -  Patients with organ allografts (such as renal transplant) are excluded&#xD;
&#xD;
          -  Patients who are &lt; 90 days post allogeneic stem cell transplant will be excluded;&#xD;
             patients beyond 90 days post-allogeneic stem cell transplant with active uncontrolled&#xD;
             graft versus host disease (GVHD) &gt; grade 1 will be excluded; patients who are on a&#xD;
             stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for &gt; 2&#xD;
             weeks will be eligible but those with recent increase in the immunosuppressive&#xD;
             medication dose within last 2 weeks to control GVHD will not be included; Note:&#xD;
             subjects may be using systemic corticosteroids or topical or inhaled corticosteroids&#xD;
             post allogeneic stem cell transplant; patients requiring &gt;= 1 mg/kg prednisone for&#xD;
             GVHD management at the time of screening will not be eligible until the prednisone can&#xD;
             be weaned to &lt; 1 mg/kg; such patients should be monitored for at least 14 days and if&#xD;
             no flare of GVHD requiring re-escalation of steroids or additional interventions for&#xD;
             the GVHD they will be eligible&#xD;
&#xD;
          -  Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia&#xD;
&#xD;
          -  Active and uncontrolled disease/(active uncontrolled infection, uncontrolled&#xD;
             hypertension despite adequate medical therapy, active and uncontrolled congestive&#xD;
             heart failure New York Heart Association [NYHA] class III/IV, clinically significant&#xD;
             and uncontrolled arrhythmia) as judged by the treating physician&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus seropositivity will be excluded&#xD;
&#xD;
          -  Known to be positive for hepatitis B by surface antigen expression; known to have&#xD;
             active hepatitis C infection (positive by polymerase chain reaction or on antiviral&#xD;
             therapy for hepatitis C within the last 6 months)&#xD;
&#xD;
          -  Any other medical, psychological, or social condition that may interfere with study&#xD;
             participation or compliance, or compromise patient safety in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  All other significant diseases (for example, inflammatory bowel disease, uncontrolled&#xD;
             asthma), which, in the opinion of the investigator, might impair the subject's&#xD;
             tolerance of trial treatment&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Known alcohol or drug abuse within the last 1 year&#xD;
&#xD;
          -  Vaccination within 4 weeks of the first dose of avelumab and while on trial is&#xD;
             prohibited except for administration of inactivated vaccines&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Subject has a history of other malignancies prior to study entry, with the exception&#xD;
             of: adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of&#xD;
             breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the&#xD;
             skin; previous malignancy confirmed and surgically resected (or treated with other&#xD;
             modalities) with curative intent or completed definitive therapy (chemotherapy,&#xD;
             radiation, others) for the malignancy at least 1 year prior to the date of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval Daver</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02953561/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 2017 to February 2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Azacitidine, Avelumab)</title>
          <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given subcutaneous or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Azacitidine, Avelumab)</title>
          <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="22" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Response</title>
        <description>Complete Response (CR) + Partial Remission (PR) + Complete Remission with incomplete recovery (CRi) + Clinical Benefit. CR = normalization of peripheral blood (PB) and bone marrow (BM) with &lt;/= 5% BM blasts, PB granulocyte count &gt;/= (1.0 x 10^9/L, and a platelet count &gt;/= 100 x 10^9/L). PR = same as CR except presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. CRi meets all criteria for CR except for platelet recovery to &gt;100 x 10^9/L and/or granulocyte count &gt; (1.0 x 10^9/L). MLFS is BM with &lt;/= 5% BM blasts with no PB recovery. Hematologic Improvement is platelets increase by &gt;/= 30 x 10^9/L untransfused (if &lt;20 at pretherapy); or granulocytes increase by 100% and to &gt;0.5 x 10^9/L (if lower than that pre-therapy); or hemoglobin increase by 2 g/dl; or transfusion independent; or splenomegaly reduction by &gt; 50%; or monocytosis reduction by &gt; 50% if pretreatment &gt; 5 x 109/L, or BM or PB Blasts decrease by &gt;/= 50%.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Of the 19 participants registered, 17 participants were evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Azacitidine, Avelumab)</title>
            <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response</title>
          <description>Complete Response (CR) + Partial Remission (PR) + Complete Remission with incomplete recovery (CRi) + Clinical Benefit. CR = normalization of peripheral blood (PB) and bone marrow (BM) with &lt;/= 5% BM blasts, PB granulocyte count &gt;/= (1.0 x 10^9/L, and a platelet count &gt;/= 100 x 10^9/L). PR = same as CR except presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. CRi meets all criteria for CR except for platelet recovery to &gt;100 x 10^9/L and/or granulocyte count &gt; (1.0 x 10^9/L). MLFS is BM with &lt;/= 5% BM blasts with no PB recovery. Hematologic Improvement is platelets increase by &gt;/= 30 x 10^9/L untransfused (if &lt;20 at pretherapy); or granulocytes increase by 100% and to &gt;0.5 x 10^9/L (if lower than that pre-therapy); or hemoglobin increase by 2 g/dl; or transfusion independent; or splenomegaly reduction by &gt; 50%; or monocytosis reduction by &gt; 50% if pretreatment &gt; 5 x 109/L, or BM or PB Blasts decrease by &gt;/= 50%.</description>
          <population>Of the 19 participants registered, 17 participants were evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Azacitidine, Avelumab)</title>
            <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="6.5" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Distribution of OS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Azacitidine, Avelumab)</title>
            <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Distribution of OS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="0.1" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Distribution of PFS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Azacitidine, Avelumab)</title>
            <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Distribution of PFS will be estimated using the method of Kaplan and Meier. Comparisons of time-to-event endpoints by important subgroups will be made using the log-rank tests.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Azacitidine, Avelumab)</title>
          <description>Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Avelumab: Given IV&#xD;
Azacitidine: Given SC or IV&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Metabolism and Nutrition Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cbills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucosal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Alanine Aminotransferase Increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet Count Decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>White Blood Count Decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Muscle Weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naval Daver MD./Associate Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-794-4392</phone>
      <email>ndaver@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

